Welcome to our dedicated page for CVS HEALTH SEC filings (Ticker: CVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CVS HEALTH's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CVS HEALTH's regulatory disclosures and financial reporting.
CVS Health Corporation reported changes to its Board of Directors. On August 13, 2026, Larry M. Robbins resigned from the Board, effective immediately, with the company stating his departure did not result from any disagreement over operations, policies or practices. On August 17, 2026, the Board appointed Teresa Heitsenrether, Executive Vice President and Chief Data & Analytics Officer of JPMorgan Chase & Co., to join the Board effective November 18, 2026. She was determined to be independent under New York Stock Exchange rules and the company’s Corporate Governance Guidelines and will receive compensation consistent with other non‑employee directors, prorated to reflect her start date.
CVS Health highlighted its scale as of June 30, 2026, including approximately 9,000 retail pharmacy locations, more than 1,000 walk‑in and primary care clinics, a pharmacy benefits manager with about 87 million plan members, and health insurance products and services serving an estimated 37 million people.
Dodge & Cox reported its ownership position in CVS Health Corporation common stock as of June 30, 2026. The firm beneficially owned 50,012,765 shares, representing 3.9% of the outstanding common stock. Dodge & Cox had sole voting power over 47,541,860 shares and sole dispositive power over 50,012,765 shares, with no shared voting or dispositive power. The filing characterizes this holding as ownership of 5 percent or less of the class.
CVS HEALTH Corp, as an institutional investment manager, submitted a Form 13F holdings report. The report covers 21 reportable positions with an aggregate Form 13F information table value total of 225,165,890. No other investment managers are included in this report.
CVS Health reported strong results for the three months ended June 30, 2026. Total revenues were $106.1 billion, up 7.3% year-over-year. GAAP diluted EPS rose to $2.31 from $0.80, and Adjusted EPS increased to $2.58 from $1.81. Operating income was $4.7 billion, up 97.5%, with adjusted operating income up 35.4% to $5.2 billion. Year-to-date cash flow from operations reached $10.6 billion.
In the Health Care Benefits segment, revenues grew 3.5% and adjusted operating income increased 85.5% to $2.4 billion, while the medical benefit ratio improved to 87.4%. Health Services revenues rose 11.5% to $51.8 billion with 10.0% higher adjusted operating income, and Pharmacy & Consumer Wellness revenues inched up 0.7% as adjusted operating income grew 10.2% and prescriptions filled rose 4.3%. CVS raised its full-year 2026 guidance, increasing GAAP diluted EPS to $6.84–$7.04, Adjusted EPS to $7.90–$8.10, and cash flow from operations to at least $11.5 billion. The company also highlighted GLP-1 support initiatives and deployment of agentic AI tools across call centers and claims processing.
CVS Health Corp senior vice president James David Clark reported a Form 4 showing a withholding of 454 restricted common shares on June 26, 2026. The shares were withheld by CVS to cover FICA taxes because he is retirement eligible, not as an open-market sale. After this tax-withholding disposition, he directly holds 27,606 CVS shares.
CVS Health executive vice president and chief financial officer Brian Newman reported a routine tax-related share disposition. He surrendered 2,478 shares of common stock at $90.98 per share to cover withholding taxes due when a restricted stock unit award vested and settled. After this non-market transaction, he continues to hold 3,008 CVS shares directly.
CVS Health Corp executive Amy Compton-Phillips reported a tax-related share disposition tied to equity compensation. On the reported date, 7,618 shares of CVS common stock were surrendered to cover withholding taxes due when a restricted stock unit award vested and settled.
These shares were not sold in an open-market transaction but used as payment of tax obligations. After this tax-withholding event, Compton-Phillips directly owned 9,557 shares of CVS common stock.
CVS Health director Fernando Aguirre reported returning shares of common stock to the company. On May 20, he disposed of 30,437 shares of CVS common stock to the issuer at a weighted average price of $93.775 per share. On May 21, he disposed of an additional 1,563 shares to the issuer at a weighted average price of $93.501 per share, with individual trades that day ranging between $93.50 and $94.01 per share. After these transactions, he directly held 10,513 CVS shares, and no derivative securities were reported in this filing.
CVS submitted a Form 144 notice reporting an intended sale of 32,000 shares of Common Stock in connection with compensation, with the sale date shown as 11/20/2025. The filing lists brokers and numeric entries including 05/20/2026.